> ## Content Index
> Fetch the complete content index at: https://bioweek.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Daraxonrasib Approval Shifts Pancreatic Oncology from Cytotoxic Care to RAS-Targeted Precision
- URL: https://bioweek.com/daraxonrasib-approval-shifts-pancreatic-oncology-from-cytotoxic-care-to-ras-targeted-precision/
- Published: 2026-08-31T05:02:29.000Z
- Updated: 2026-08-31T05:02:29.000Z
- Description: The FDA's landmark approval of Revolution Medicines' daraxonrasib (Rasonque) introduces the first multi-selective RAS(ON) tri-complex inhibitor for metastatic pancreatic adenocarcinoma, doubling overall survival over standard chemotherapy.
- Author: BioWeek
- Tags: Pipeline, Science

The U.S. Food and Drug Administration granted approval on August 26, 2026, to [daraxonrasib](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daraxonrasib-metastatic-pancreatic-adenocarcinoma?ref=bioweek.com) (brand name Rasonque), marking the first targeted therapy approved for adult patients with metastatic pancreatic ductal adenocarcinoma across broad RAS genotypes. Developed by Revolution Medicines, the once-daily oral 300 mg tablet is indicated for patients who progressed following at least one prior systemic therapy or who cannot tolerate multiagent chemotherapy regimens.

The regulatory decision arrived roughly 6.5 months ahead of the agency's prescription drug user fee goal date, supported by the FDA Commissioner's National Priority Review Voucher pilot and Project Orbis international review frameworks. For decades, metastatic pancreatic cancer remained one of the most recalcitrant solid tumors in clinical oncology, largely managed with intensive cytotoxic combination regimens like FOLFIRINOX or gemcitabine plus nab-paclitaxel that offer modest survival extensions alongside substantial toxicities.

### Tri-Complex Biology Breaks the Undruggable Barrier

For over 40 years, the RAS GTPase family was considered an intractable, undruggable target in oncology. While early covalent KRAS G12C inhibitors unlocked a small subpopulation of non-small cell lung and colorectal cancers, pancreatic cancer is predominantly driven by non-G12C variants, including KRAS G12D, G12V, and G12R, which lack the nucleophilic cysteine residue needed for covalent tethering.

Daraxonrasib overcomes this structural obstacle through noncovalent tri-complex chemistry. Rather than attempting to occupy shallow GTP-binding pockets directly, the small molecule binds intracellular chaperone protein [cyclophilin](https://doi.org/10.1021/acs.jmedchem.4c02314?ref=bioweek.com) A (CypA). The resulting binary complex creates an artificial composite interface that selectively binds the active, GTP-bound state of RAS proteins, termed RAS(ON).

By forming a stable ternary complex of CypA, daraxonrasib, and RAS(ON), the therapy sterically blocks RAS from interacting with downstream effector kinases, including RAF, MEK, and PI3K. Crucially, this mechanism operates across multiple mutant variants as well as wild-type RAS without requiring mutant-specific covalent handles, allowing broad activity across diverse RAS-driven tumors without requiring a companion diagnostic test.

### Phase 3 RASolute 302 Demonstrates Unprecedented Survival Gains

The FDA approval was grounded in clinical results from the randomized, open-label, multicenter Phase 3 [RASolute](https://www.revmed.com/media/news/13366/u-s-fda-approves-revolution-medicines-rasonquetm-daraxonrasib-the-first-broad-ras-targeted-medicine-in-metastatic-pancreatic-cancer?ref=bioweek.com) 302 trial (NCT06625320), which enrolled 500 patients with metastatic pancreatic ductal adenocarcinoma whose disease had progressed after one prior line of therapy. Participants were randomized 1:1 to receive either oral daraxonrasib at 300 mg daily or investigator's choice of standard-of-care cytotoxic chemotherapy regimens.

The trial met both primary endpoints in patients harboring RAS G12 mutations and in the broader intent-to-treat (ITT) population, with results published in the *New England Journal of Medicine*:

- **Overall Survival (OS):** In the overall ITT cohort, median OS reached 13.2 months (95% CI: 10.0–NE) in the daraxonrasib arm compared to 6.7 months (95% CI: 5.8–8.0) in the chemotherapy arm, representing a 60% reduction in the risk of death (hazard ratio 0.40; 95% CI: 0.30–0.53; p < 0.0001).
- **Progression-Free Survival (PFS):** Median PFS was 7.2 months (95% CI: 5.7–7.5) with daraxonrasib versus 3.6 months (95% CI: 2.9–4.2) for standard chemotherapy, demonstrating a 51% reduction in disease progression or mortality (hazard ratio 0.49; 95% CI: 0.38–0.64; p < 0.0001).
- **Objective Response Rate (ORR):** Independent central review confirmed an ORR of 30% (95% CI: 25–36%) for daraxonrasib compared to 11% (95% CI: 7–15%) with chemotherapy (p < 0.0001).

Patient-reported outcomes showed corresponding clinical value. Median time to deterioration of global health status was extended to 5.7 months on daraxonrasib versus 2.6 months on chemotherapy (hazard ratio 0.60; p < 0.001), while time to pain worsening reached 9.2 months compared to 3.8 months (hazard ratio 0.51; p < 0.001).

### Tolerability Profile and Class-Specific Monitoring

While daraxonrasib replaces cytotoxic infusions with an oral daily pill, its multi-selective RAS(ON) inhibition profile induces distinct class-related toxicities that require clinical oversight and pre-emptive management. Because wild-type RAS signaling supports physiological epithelial homeostasis, on-target cutaneous and mucosal adverse reactions are common.

Dermatologic toxicities occurred in 86% of clinical trial participants (10% Grade 3), presenting as papulopustular rash, pruritus, dry skin, paronychia, and fissures. Official prescribing instructions advise initiating prophylactic topical corticosteroids, emollient creams, sunscreen, and oral antibiotics such as doxycycline prior to the first dose.

Additional reported adverse reactions include stomatitis in 57% of patients (9% Grade 3) and diarrhea in 63% (6% Grade 3). Serious adverse events occurred in 30% of trial patients, with Grade 3 or 4 warnings established for rare gastrointestinal perforation (0.9%) and interstitial lung disease or pneumonitis (2.4%). Across the pivotal trial, adverse events led to treatment discontinuation in 2.9% of participants.

### Commercial Trajectory and Pipeline Expansion

Revolution Medicines has made 300 mg tablets available commercially in the United States, supported by its dedicated patient assistance infrastructure, the (ON)Path program. Beyond the immediate second-line pancreatic cancer indication, the company is advancing daraxonrasib in first-line combination settings and expanding Phase 3 evaluation into non-small cell lung cancer harboring non-G12C KRAS mutations.

With international regulatory submissions underway across Europe under the European Medicines Agency's phased review framework and in Japan with PMDA, daraxonrasib's approval establishes a new benchmark for targeted oncology in tumor types long considered unapproachable by small-molecule drug discovery.